Repligen Q3 2026 slides: record revenue, raised guidance, margins expand

Repligen (RGEN) reported Q3 2026 revenue of $209M, up 11% YoY, and raised full-year guidance. Chromatography and Proteins segments drove growth, while Filtration declined. Adjusted EPS was $0.53, beating estimates. Shares fell 2.25% premarket despite record revenue and raised guidance, likely due to near-term challenges.

Original reporting
Published Oct 27, 2026, 1:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The earnings beat and guidance lift provide a fresh catalyst that could drive the stock higher, though margin concerns may cause volatility.

02

Market read

First‑time disclosure of earnings and guidance for a mid‑cap biotech equipment firm, with material financial figures.

03

What to watch

Integration of the BioLife acquisition may introduce execution risk not reflected in the guidance

Relevance 9/10Novelty 9/10Timing: premarket today

Background

Repligen reported Q3 2026 results, beating earnings expectations and raising full-year guidance amid record revenue growth.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Q3 2026 earnings release with record $209M revenue and raised full-year guidance

Expected impact

likely upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

The company disclosed fresh quarterly numbers and lifted guidance for the first time, a material catalyst for the stock

Market effects

Bioprocessing equipment sector may see broader optimism from Repligen's growth and guidance raise

Asia‑Pacific equipment demand highlighted, could boost related regional suppliers

Strong guidance may influence investor sentiment toward biotech manufacturing stocks globally

Counterpoint

Margin pressure and filtration weakness could limit upside, prompting short‑term sell‑off

Key entities

  • Repligen Corporation

    Bioprocessing equipment supplier reporting Q3 2026 results

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.